BENITIONSClinical Trial Intelligence

A Study of a Mobile Phone Application Measuring the Eyes Before and After Medication

Не применимо Завершено NCT06629740

ЗаболеваниеSubstance Use Disorder
ФазаНе применимо
СпонсорKontigo Care AB
СтатусЗавершено
Участники34 участн.
ВмешательствоMeasurements with a eHealth system
Дата начала1.11.2024
Дата завершения17.03.2025
Публикация результатов20.07.2026

Кратко

This is a post-market clinical follow-up study on an approved CE-marked eHealth system where a mobile phone application is used to measure the pupils and eye measurements to monitor the use of different drug substances. The goal of the study is to collect additional information when using the system and to improve the current models for indicating the use of cannabinoids and phenethylamines. Drug intake of cannabinoid or phenethylamine will in this study be simulated using two commonly used medicines. The study will include healthy volunteers where each participant will participate in the study for approximately 10 days. The participant will be using the mobile phone application for about a week, first at the clinic and then in the home environment. After approximately a week the participant will visit the clinic to be administered with the selected medicine whereafter the mobile phone application will be used for up to 5 hours. A final phone call will be taken place at approximately day 10, whereafter the participant has completed the study.

Verify if Self-administered Eye Scanning Using a Mobile Phone Application, Using Native Key Features (Alone or in Predefined Combination(s)), Can Indicate Use of Each Medicine (D1-D2).

Day 7 (+/- 2 days) · Key features

Cannabinoid3 Key features
Phenethylamine9 Key features
Cannabinoid7 Key features
Phenethylamine8 Key features
p-value0.038

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.